Skip to main content
Contact Us
Subscribe
E-Edition
61°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
argenx SE - American Depositary Shares
(NQ:
ARGX
)
581.21
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about argenx SE - American Depositary Shares
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
argenx Appoints Ana Cespedes to Board of Directors
December 12, 2022
From
argenx SE
Via
GlobeNewswire
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
December 10, 2022
From
argenx SE
Via
GlobeNewswire
Analyst Ratings for argenx
December 07, 2022
Via
Benzinga
Expert Ratings for argenx
December 07, 2022
Via
Benzinga
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
November 30, 2022
Via
Benzinga
argenx Enters Into Agreement To Acquire Priority Review Voucher
November 30, 2022
From
argenx SE
Via
GlobeNewswire
7 Analysts Have This to Say About argenx
October 18, 2022
argenx (NASDAQ:ARGX) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Argenx's Drug Scores European Approval For Muscular Fatigue Disorder
August 11, 2022
Via
Benzinga
Argenx's Vyvgart To 'Achieve Blockbuster Status,' This Analyst Says With 6% Price Target Hike
July 29, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
December 01, 2022
During Thursday's session, 108 stocks hit new 52-week highs.
Via
Benzinga
Argenx's Flagship Neuromuscular Treatment For Subcutaneous Injection Goes Under Priority FDA Review
November 22, 2022
Via
Benzinga
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
November 22, 2022
From
argenx SE
Via
GlobeNewswire
argenx to Present at Upcoming Investor Conferences
November 07, 2022
From
argenx SE
Via
GlobeNewswire
McDonald's To Rally Over 13%? Here Are 5 Other Price Target Changes For Friday
October 28, 2022
Wedbush raised McDonald's Corporation (NYSE: MCD) price target from $265 to $300. Wedbush analyst Nick Setyan maintained the stock with an Outperform rating. McDonald's shares rose 3.3% to close at...
Via
Benzinga
argenx: Q2 Earnings Insights
July 28, 2022
argenx (NASDAQ:ARGX) reported its Q2 earnings results on Thursday, July 28, 2022 at 01:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Recap: argenx Q2 Earnings
July 28, 2022
argenx (NASDAQ:ARGX) reported its Q2 earnings results on Thursday, July 28, 2022 at 01:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
What 5 Analyst Ratings Have To Say About argenx
July 25, 2022
Analysts have provided the following ratings for argenx (NASDAQ:ARGX) within the last quarter:
Via
Benzinga
Recap: argenx Q3 Earnings
October 27, 2022
argenx (NASDAQ:ARGX) reported its Q3 earnings results on Thursday, October 27, 2022 at 01:00 AM. Here's what investors need to know about the announcement. Earnings argenx missed estimated earnings by...
Via
Benzinga
argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
October 27, 2022
From
argenx SE
Via
GlobeNewswire
argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
October 20, 2022
From
argenx SE
Via
GlobeNewswire
Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say
September 29, 2022
Via
Benzinga
Argenx Seeks FDA Nod For Its Flagship Neuromuscular Treatment Formulated For Subcutaneous Injection
September 21, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
October 12, 2022
Upgrades
Via
Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
August 11, 2022
Via
Benzinga
Argenx Gets European Marketing Authorization For Neuromuscular Disorder Candidate
August 11, 2022
The European Commission (EC) has granted marketing authorization for Argenx’s (NASDAQ: ARGX) lead asset VYVGART (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022
July 29, 2022
Via
Benzinga
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
July 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022
July 28, 2022
From
argenx SE
Via
GlobeNewswire
argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update
July 28, 2022
From
argenx SE
Via
GlobeNewswire
Piper Sandler Maintains Overweight Rating for argenx: Here's What You Need To Know
July 25, 2022
Piper Sandler has decided to maintain its Overweight rating of argenx (NASDAQ:ARGX) and raise its price target from $415.00 to $425.00. Shares of argenx are trading up 1.84% over the last 24 hours, at...
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.